Progress of The Relationship Between p53 and c-erbB-2 in Gastric Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

WANG Hongbo ¹ , JI Changsheng ² , ZHANG Jun ¹

1.Department of Gastrointestinal Surgery, The People’s Hospital of Jimo City, Shandong Province, Jimo 266200, China;;
2.Department of Pathology, The People’s Hospital of Jimo City, Shandong Province, Jimo 266200, China;

Corresponding author：

Keywords：

p53 gene; c-erbB-2 gene; Gastric cancer; Prognosis

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the progress of the relationship between the tumor suppressor gene p53 and oncogene c-erbB-2 and gastric cancer in recent years.
Methods Relevant literatures about p53 and c-erbB-2 in gastric cancer were collected and analyzed.
Results The mutation of p53 gene and the over-expression of c-erbB-2 gene were a common event in gastric cancer. The mutation of p53 gene was correlated with the location of gastric cancer and its aggressive biological behavior. The over-expression of c-erbB-2 gene could be used as an independent prognostic parameter in gastric cancer. The drugs targeted on p53 and c-erbB-2 gene were being developed.
Conclusion Further research on the role of p53 and c-erbB-2 gene in the development of gastric cancer is helpful to understand the biological behavior and provide theoretical basis for gene therapy.

Citation： WANG Hongbo ,JI Changsheng,ZHANG Jun. Progress of The Relationship Between p53 and c-erbB-2 in Gastric Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2010, 17(8): 880-884. doi: Copy

1.	陈志新, 张波. 胃癌综合治疗现状及展望 [J]. 中国普外基础与临床杂志, 2008; 15(1): 7173.
2.	Smith MG, Hold GL, Tahara E, et al. Cellular and molecular aspects of gastric cancer [J]. World J Gastroenterol, 2006; 12(19): 29792990.
3.	Cunningham SC, Kamangar F, Kim MP, et al. Claudin4, mitogenactivated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions [J]. Cancer Epidemiol Biomarkers Prev, 2006; 15(2): 281287.
4.	Meireles SI, Cristo EB, Carvalho AF, et al. Molecular classifiers for gastric cancer and nonmalignant diseases of the gastric mucosa [J]. Cancer Res, 2004; 64(4): 12551265.
5.	Sun Y, Li JY, He JS, et al. Tissue microarray analysis of multiple gene expression in intestinal metaplasia, dysplasia and carcinoma of the stomach [J]. Histopathology, 2005; 46(5): 505514.
6.	Correa P. Human gastric carcinogenesis: a multistep and multifactorial processFirst American Cancer Society Award Lecture on Cancer Epidemiology and Prevention [J]. Cancer Res, 1992; 52(24): 67356740.
7.	Busuttil RA, Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis [J]. J Gastroenterol Hepatol, 2009; 24(2):193201.
8.	Tamura G. Alterations of tumor suppressor and tumorrelated genes in the development and progression of gastric cancer [J]. World J Gastroenterol, 2006; 12(2): 192198.
9.	Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities [J]. Cell Death differ, 2006; 13(6): 951961.
10.	Egashira A, Morita M, Kakeji Y, et al. p53 gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: results in Japan and comparisons with other countries [J]. Cancer Sci, 2007; 98(8): 11521156.
11.	Kim E, Giese A, Deppert W. Wildtype p53 in cancer cells: when a guardian turns into a blackguard [J]. Biochem Pharmacol, 2009; 77(1):1120.
12.	Han JA, Kim J, Ongusaha PP, et al. p53mediated induction of Cox2 counteracts p53 or genotoxic stressinduced apoptosis [J]. EMBO J, 2002; 21(21): 56355644.
13.	Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database： New online mutation analysis and recommendations to users [J]. Hum Mutat, 2002; 19(6): 607614.
14.	PintodeSousa J, Silva F, David L, et al. Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma [J]. Histopathology, 2004; 44(4): 323331.
15.	Tamura G, Sato K, Akiyama S, et al. Molecular characterization of undifferentiatedtype gastric carcinoma [J]. Lab Invest, 2001; 81(4): 593598.
16.	Shiao YH, Palli D, Buzard GS, et al. Implications of p53 mutation spectrum for cancer etiology in gastric cancers of various histologic types from a highrisk area of central Italy [J]. Carcinogenesis, 1998; 19 (12): 21452149.
17.	Morgan C, Jenkins GJ, Ashton T, et al. Detection of p53 mutations in precancerous gastric tissue [J]. Br J Cancer, 2003; 89(7): 13141319.
18.	Taguchi A, Ohmiya N, Itoh A, et al. Severity of atrophic gastritis related to antiparietal cell antibody and gastric carcinogenesis, including p53 mutations [J]. J Gastroenterol Hepatol, 2006; 21(3): 545551.
19.	Azarhoush R, Keshtkar AA, Amiriani T, et al. Relationship between p53 expression and gastric cancers in cardia and antrum [J]. Arch Iran Med, 2008; 11(5): 502506.
20.	Tajima Y, Yamazaki K, Makino R, et al. Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach [J]. Br J Cancer, 2007; 96(4): 631638.
21.	Nayak SK, Panesar PS, Kumar H. p53Induced apoptosis and inhibitors of p53 [J]. Curr Med Chem, 2009; 16(21): 26272640.
22.	Ohnishi T, Takahashi A, Mori E, et al. p53 Targeting can enhance cancer therapy via radiation, heat and anticancer agents [J]. Anticancer Agents Med Chem, 2008; 8(5): 564570.
23.	Yano T, Ochiai A, Doi T, et al. Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit [J]. J Clin Oncol, 2004; 22(14S): 4053.
24.	Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer [J]. Tumori, 2008; 94(3): 370383.
25.	Schuell B, Gruenberger T, Scheithauer W, et al. HER2/neu protein expression in colorectal cancer [J]. BMC Cancer, 2006; 6: 123127.
26.	Eltze E, Wülfing C, Von Struensee D, et al. Cox2 and Her2/neu coexpression in invasive bladder cancer [J]. Int J Oncol, 2005; 26(6):15251531.
27.	Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas [J]. J Natl Cancer Inst, 1986; 77(5): 10471052.
28.	Park DI, Yun JW, Park JH, et al. HER2/neu amplification is an independent prognostic factor in gastric cancer [J]. Dig Dis Sci, 2006; 51(8): 13711379.
29.	Gravalos C, Mrquez A, GarcíaCarbonero R, et al. Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer (AGC) patients (pts): A prospective study [C]. 2007 Gastrointestinal Cancers Symposium， 2007； Abstract No: 89.
30.	Lordick F, Bang YJ, Kang YK, et al. HER2positive advanced gastric cancer: similar HER2positivity levels to breast cancer [J]. Eur J Cancer, 2007; 5(4): 271277.
31.	Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER2 in gastric carcinoma: association with Topoisomerase II gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab [J]. Ann Oncol, 2005; 16(2): 273278.
32.	Nicholas G, Cripps C, Au HP, et al. Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER2 [J]. ESMO, 2006; 17 (Suppl 9): 316.
33.	汪劭婷, 朱朝晖, 李小毅. 胃癌新辅助化疗疗效临床评价方法及进展 [J]. 中国普外基础与临床杂志, 2010; 17(2): 200204.
34.	Sastre J, GarciaSaenz JA, DiazRubio E. Chemotherapy for gastric cancer [J]. World J Gastroenterol, 2006; 12(2): 204213.
35.	Rech J, Arnold D, Folprecht G, et al. A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER2 positive gastric cancer [J]. ESMO, 2006; 17 (Suppl 9): 314.
36.	Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin [J]. Int J Oncol, 2008; 32(1): 8995.
37.	MezaJunco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer [J]. Expert Opin Biol Ther, 2009; 9(12):15431551.
38.	Kang Y, Bang Y, Lordick F, et al. Incidence of gastric and gastroesophageal cancer in the ToGA trial: Correlation with HER2 positivity [C]. 2008 Gastrointestinal Cancers Symposium, 2008: 75 (Abstr 11).
39.	FujimotoOuchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models [J]. Cancer Chemother Pharmacol, 2007; 59(6): 795805.
40.	Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: A phase Ⅲ study of trastuzumab added to standard chemotherapy (CT) in firstline human epidermal growth factor receptor 2 (HER2)positive advanced gastric cancer (GC) [J]. J Clin Oncol, 2009; 27(18S): LBA4509.

1. 陈志新, 张波. 胃癌综合治疗现状及展望 [J]. 中国普外基础与临床杂志, 2008; 15(1): 7173.
2. Smith MG, Hold GL, Tahara E, et al. Cellular and molecular aspects of gastric cancer [J]. World J Gastroenterol, 2006; 12(19): 29792990.
3. Cunningham SC, Kamangar F, Kim MP, et al. Claudin4, mitogenactivated protein kinase kinase 4, and stratifin are markers of gastric adenocarcinoma precursor lesions [J]. Cancer Epidemiol Biomarkers Prev, 2006; 15(2): 281287.
4. Meireles SI, Cristo EB, Carvalho AF, et al. Molecular classifiers for gastric cancer and nonmalignant diseases of the gastric mucosa [J]. Cancer Res, 2004; 64(4): 12551265.
5. Sun Y, Li JY, He JS, et al. Tissue microarray analysis of multiple gene expression in intestinal metaplasia, dysplasia and carcinoma of the stomach [J]. Histopathology, 2005; 46(5): 505514.
6. Correa P. Human gastric carcinogenesis: a multistep and multifactorial processFirst American Cancer Society Award Lecture on Cancer Epidemiology and Prevention [J]. Cancer Res, 1992; 52(24): 67356740.
7. Busuttil RA, Boussioutas A. Intestinal metaplasia: a premalignant lesion involved in gastric carcinogenesis [J]. J Gastroenterol Hepatol, 2009; 24(2):193201.
8. Tamura G. Alterations of tumor suppressor and tumorrelated genes in the development and progression of gastric cancer [J]. World J Gastroenterol, 2006; 12(2): 192198.
9. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities [J]. Cell Death differ, 2006; 13(6): 951961.
10. Egashira A, Morita M, Kakeji Y, et al. p53 gene mutations in esophageal squamous cell carcinoma and their relevance to etiology and pathogenesis: results in Japan and comparisons with other countries [J]. Cancer Sci, 2007; 98(8): 11521156.
11. Kim E, Giese A, Deppert W. Wildtype p53 in cancer cells: when a guardian turns into a blackguard [J]. Biochem Pharmacol, 2009; 77(1):1120.
12. Han JA, Kim J, Ongusaha PP, et al. p53mediated induction of Cox2 counteracts p53 or genotoxic stressinduced apoptosis [J]. EMBO J, 2002; 21(21): 56355644.
13. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database： New online mutation analysis and recommendations to users [J]. Hum Mutat, 2002; 19(6): 607614.
14. PintodeSousa J, Silva F, David L, et al. Clinicopathological significance and survival influence of p53 protein expression in gastric carcinoma [J]. Histopathology, 2004; 44(4): 323331.
15. Tamura G, Sato K, Akiyama S, et al. Molecular characterization of undifferentiatedtype gastric carcinoma [J]. Lab Invest, 2001; 81(4): 593598.
16. Shiao YH, Palli D, Buzard GS, et al. Implications of p53 mutation spectrum for cancer etiology in gastric cancers of various histologic types from a highrisk area of central Italy [J]. Carcinogenesis, 1998; 19 (12): 21452149.
17. Morgan C, Jenkins GJ, Ashton T, et al. Detection of p53 mutations in precancerous gastric tissue [J]. Br J Cancer, 2003; 89(7): 13141319.
18. Taguchi A, Ohmiya N, Itoh A, et al. Severity of atrophic gastritis related to antiparietal cell antibody and gastric carcinogenesis, including p53 mutations [J]. J Gastroenterol Hepatol, 2006; 21(3): 545551.
19. Azarhoush R, Keshtkar AA, Amiriani T, et al. Relationship between p53 expression and gastric cancers in cardia and antrum [J]. Arch Iran Med, 2008; 11(5): 502506.
20. Tajima Y, Yamazaki K, Makino R, et al. Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach [J]. Br J Cancer, 2007; 96(4): 631638.
21. Nayak SK, Panesar PS, Kumar H. p53Induced apoptosis and inhibitors of p53 [J]. Curr Med Chem, 2009; 16(21): 26272640.
22. Ohnishi T, Takahashi A, Mori E, et al. p53 Targeting can enhance cancer therapy via radiation, heat and anticancer agents [J]. Anticancer Agents Med Chem, 2008; 8(5): 564570.
23. Yano T, Ochiai A, Doi T, et al. Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit [J]. J Clin Oncol, 2004; 22(14S): 4053.
24. Rastelli F, Crispino S. Factors predictive of response to hormone therapy in breast cancer [J]. Tumori, 2008; 94(3): 370383.
25. Schuell B, Gruenberger T, Scheithauer W, et al. HER2/neu protein expression in colorectal cancer [J]. BMC Cancer, 2006; 6: 123127.
26. Eltze E, Wülfing C, Von Struensee D, et al. Cox2 and Her2/neu coexpression in invasive bladder cancer [J]. Int J Oncol, 2005; 26(6):15251531.
27. Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas [J]. J Natl Cancer Inst, 1986; 77(5): 10471052.
28. Park DI, Yun JW, Park JH, et al. HER2/neu amplification is an independent prognostic factor in gastric cancer [J]. Dig Dis Sci, 2006; 51(8): 13711379.
29. Gravalos C, Mrquez A, GarcíaCarbonero R, et al. Correlation between Her2/neu overexpression/amplification and clinicopathological parameters in advanced gastric cancer (AGC) patients (pts): A prospective study [C]. 2007 Gastrointestinal Cancers Symposium， 2007； Abstract No: 89.
30. Lordick F, Bang YJ, Kang YK, et al. HER2positive advanced gastric cancer: similar HER2positivity levels to breast cancer [J]. Eur J Cancer, 2007; 5(4): 271277.
31. Tanner M, Hollmén M, Junttila TT, et al. Amplification of HER2 in gastric carcinoma: association with Topoisomerase II gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab [J]. Ann Oncol, 2005; 16(2): 273278.
32. Nicholas G, Cripps C, Au HP, et al. Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER2 [J]. ESMO, 2006; 17 (Suppl 9): 316.
33. 汪劭婷, 朱朝晖, 李小毅. 胃癌新辅助化疗疗效临床评价方法及进展 [J]. 中国普外基础与临床杂志, 2010; 17(2): 200204.
34. Sastre J, GarciaSaenz JA, DiazRubio E. Chemotherapy for gastric cancer [J]. World J Gastroenterol, 2006; 12(2): 204213.
35. Rech J, Arnold D, Folprecht G, et al. A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER2 positive gastric cancer [J]. ESMO, 2006; 17 (Suppl 9): 314.
36. Kim SY, Kim HP, Kim YJ, et al. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin [J]. Int J Oncol, 2008; 32(1): 8995.
37. MezaJunco J, Au HJ, Sawyer MB. Trastuzumab for gastric cancer [J]. Expert Opin Biol Ther, 2009; 9(12):15431551.
38. Kang Y, Bang Y, Lordick F, et al. Incidence of gastric and gastroesophageal cancer in the ToGA trial: Correlation with HER2 positivity [C]. 2008 Gastrointestinal Cancers Symposium, 2008: 75 (Abstr 11).
39. FujimotoOuchi K, Sekiguchi F, Yasuno H, et al. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models [J]. Cancer Chemother Pharmacol, 2007; 59(6): 795805.
40. Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: A phase Ⅲ study of trastuzumab added to standard chemotherapy (CT) in firstline human epidermal growth factor receptor 2 (HER2)positive advanced gastric cancer (GC) [J]. J Clin Oncol, 2009; 27(18S): LBA4509.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Progress of The Relationship Between p53 and c-erbB-2 in Gastric Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content